Free accessResearch articleFirst published online 2002-06
Beneficial Effects of Therapy on the Progression of Structural Remodeling During Healing After Reperfused and Nonreperfused Myocardial Infarction: Different Effects on Different Parameters
Background: Structural left ventricular remodeling after myocardial infarction is a complex process with several pathophysiologic descriptors that can be modified by pharmacotherapy. However, the possibility that different classes of antiremodeling agents might exert different effects on different remodeling parameters after reperfused and nonreperfused myocardial infarction has not been systematically studied.
Methods and Results: We measured detailed left ventricular remodeling parameters in vivo (echocardiograms) repeatedly over 6 weeks and ex vivo (planimetry) at 6 weeks after myocardial infarction in 36 dogs randomized (factorial design) after reperfused or nonreperfused myocardial infarction to 6 weeks of twice daily oral therapy with the calcium channel blocker amlodipine (5 mg), the angiotensin-converting enzyme inhibitor enalapril (5 mg) or placebo, and 18 matching sham or control animals. Compared to placebo and control groups over 6 weeks, both agents reduced left ventricular loading and limited overall remodeling in both reperfused and nonreperfused groups, but there were pertinent differences. Enalapril limited the increase in left ventricular asynergy in the reperfused group. Both enalapril and amlodipine limited infarct zone thinning in the nonreperfused groups but increased infarct zone thinning in the reperfused groups, despite preserved infarct zone collagen with amlodipine. Enalapril decreased left ventricular diastolic volume and mass more than amlodipine in the reperfused group and increased left ventricular ejection fraction in the nonreperfused group. Both agents limited regional and global shape deformation in reperfused and nonreperfused groups. Diastolic wall stress in the infarct zone decreased with amlodipine, and increased with enalapril and reperfusion.
Conclusions: Different antiremodeling therapies may exert different effects on different remodeling parameters during healing after reperfused myocardial infarction. Significant interactions occur during reperfusion. More than one variable may be needed for the comprehensive assessment of the antiremodeling efficacy of different therapies.
1. Jugdutt BI, Amy RW. Healing after myocardial infarction in the dog: Changes in infarct hydroxyproline and topography. J Am Coll Cardiol7:91-102, 1986
5. Jugdutt BI. Prevention of ventricular remodelling post myocardial infarction: Timing and duration of therapy. Can J Cardiol9:103-114, 1993
6.
6. Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML. Regional cardiac dilation after acute myocardial infarction: Recognition by two-dimensional echocardiography. N Engl J Med300:57-62, 1979
7.
7. Erlebacher JA, Weiss JL, Eaton LW, Kallman C, Weisfeldt ML, Bulkley BH. Late effects of acute infarct dilation on heart size. A two-dimensional Echocardiographic study. Am J Cardiol49:1120-1126, 1982
8.
8. Weisman HF, Bush DE, Mannisi JA, Weisfeldt ML, Healy B.Cellular mechanisms of myocardial infarct expansion. Circulation78:186-201, 1988
9.
9. Jugdutt BI. Identification of patients prone to infarct expansion by the degree of regional shape distortion on an early two-dimensional echocardiogram after myocardial infarction. A prospective study. Clin Cardiol13:28-40, 1990
10.
10. Gaudron P, Eilles C, Kugler I, Ertl G.Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation87:755-763, 1993
11.
11. Mallory GK, White PD, Salcedo-Salgar J.The speed of healing of myocardial infarction: a study of the pathologic anatomy in 72 cases. Am Heart J18:647-671, 1939
12.
12. Fishbein MC, Maclean D, Maroko PR. The histopathologic evolution of myocardial infarction. Chest73:843-849, 1978
13.
13. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol20:3-16, 1992
14.
14. Jugdutt BI, Wamica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Circulation78:906-919, 1988
15.
15. Sharpe N, Murphy J, Smith H, Hannan S.Treatment of patients with symptomless LV dysfunction after MI. Lancet1:255-259, 1988
16.
16. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E.Effect of captopril on progressive ventricular dilatation after anterior MI. N Engl J Med319:80-86, 1988
17.
17. Jugdutt BI. Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. Heart Failure Rev1: 115-129, 1996
18.
18. Jugdutt BI, Manyari DE, Humen DP. Detection of viability of dysfunctional myocardium in coronary heart disease. II. Echocardiography. Heart Failure Rev2:207-233, 1998
19.
19. Sutton M St.J, Pfeffer MA, Plappert T, et al, for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation89:68-75, 1994
20.
20. Jugdutt BI, Michorowski BL. Role of infarction expansion in rupture of the ventricular septum after acute myocardial infarction. A Two-Dimensional Echocardiographic study. Clin Cardiol10:641-652, 1987
21.
21. Jugdutt BI, Michorowski BL, Kappagoda TC. Exercise training after anterior Q wave myocardial infarction: Importance of regional left ventricular function and topography. J Am Coll Cardiol12:362-372, 1988
22.
22. Jugdutt BI, Basualdo CA. Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post-infarction pericarditis. Influence of other pharmacologic agents during early remodeling. Can J Cardiol5: 211-221, 1989
23.
23. Jugdutt BI, Michorowski BL, Khan MI. Effect of longterm captopril therapy on left ventricular remodeling and function during healing and canine myocardial infarction. J Am Coll Cardiol19:713-723, 1992
24.
24. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation92:926-934, 1995
25.
25. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE. Combined captopril and isosorbide dinitrate during healing after myocardial infarction. Effect on remodeling, function, mass and collagen. J Am Coll Cardiol25:1089-1096, 1995
26.
26. Jugdutt BI. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol25:1718-1725, 1995
27.
27. Jugdutt BI. Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol272:H1205-H1211, 1997
28.
28. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol28:1328-1428, 1996
29.
29. Jugdutt BI, Schwarz-Michorowski BL, Tymchak WJ, Burton JR. Prompt improvement of left ventricular function and topography with combined reperfusion and intravenous nitroglycerin in acute myocardial infarction. Cardiology88:170-179, 1997
30.
30. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation66:1146-1149, 1982
31.
31. Kloner RA, Ellis SG, Lange R, Braunwald E.Studies of experimental coronary artery reperfusion: Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation68(suppl I):18-I15, 1983
32.
32. Kloner RA, Przyklenk K, Whittaker P.Deleterious effects of oxygen radicals in ischemia/reperfusion: Resolved and unresolved issues. Circulation80:1115-1127, 1989
33.
33. Zhao M, Zhang H, Robinson TF, Factor SM, Sonnenblick EH, Eng C.Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional (“stunned”) but viable myocardium. J Am Coll Cardiol10:1322-1334, 1987
34.
34. Kloner RA, Ganote CE, Jennings RP. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest54:1496-1508, 1974
35.
35. Mehta JL, Nichols WW, Donnelly WH, et al. Protection by superoxide dismutase from myocardial dysfunction and attenuation of vasodilator reserve after coronary occlusion and reperfusion in the dog. Circ Res65:1283-1295, 1989
36.
36. Entman ML, Smith CW. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res28:1301-1311, 1994
37.
37. Becker LC, Jeremy RW, Schaper J, Schaper W.Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. Am J Physiol277: H243-H252, 1999
38.
38. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G, for the meeting participants. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation92:3132-3137, 1995
39.
39. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials. Circulation97:2202-2212, 1998
40.
40. Pfeffer MA, Greaves SC, Arnold MJ, et al, for the Healing and Afterload Reducing Therapy (HEART) Trial Investigators. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Afterload Reducing Therapy Trial. Circulation95:2643-2651, 1997
41.
41. Pfeffer JM, Pfeffer MA, Braunwald E.Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res57:84-95, 1985
42.
42. Jugdutt BI, Lucas A, Khan MI. Effect of ACE inhibition on infarct collagen deposition and remodeling during healing after transmural canine myocardial infarction. Can J Cardiol13:657-668, 1997
43.
43. van Krimpen C, Schoemaker RG, Cleutjens JPM, et al. Angiotensin I converting enzyme inhibitors and cardiac remodeling. Basic Res Cardiol86:149-155, 1991
44.
44. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of the kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev47:25-49, 1995
46. Packer M, O'Connor CM, Ghali JK, et al. for the PRAISE Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med335:1107-1114, 1996
47.
47. Jugdutt BI. Effects of amlodipine versus enalapril on left ventricular remodelling after reperfused anterior myocardial canine infarction. Can J Cardiol13:945-954, 1997
48.
48. Jugdutt BI, Musat-Marcu S.Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction. Can J Cardiol16:617-625, 2000
49.
49. Shimada S, Yoshiyama M, Takeuchi K, et al. Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction. Cardiovasc Res37:618-626, 1998
50.
50. Watanabe M, Kawaguchi H, Onozuka H, et al. Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts. J Cardiovasc Pharmacol32:248-259, 1998
51.
51. Whittaker P, Zhang HP, Kloner RA. Biphasic survival response to amlodipine after myocardial infarction in rats: Association with cardiac vascular remodeling. Cardiovasc Pathol9:85-93, 2000
52.
52. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels. An unexpected mechanism of action of a calcium channel-blocking agent. Circulation97:576-580, 1998
53.
53. Zhang X, Kichuk MR, Mital S, et al. Amlodipine promotes kinin-mediated nitric -oxide production in coronary microvessels of failing human hearts. Am J Cardiol84:27L-33L, 1999
54.
54. Jugdutt BI, Tang SB, Khan MI, Basualdo CA. Functional impact on remodeling during healing after non-Q-wave versus Q-wave anterior myocardial infarction in the dog. J Am Coll Cardiol20:722-731, 1992
55.
55. Mirsky I.Elastic properties of the myocardium: A quantitative approach with physiological and clinical applications. In: Beme RM, Sperelakis N (eds). Handbook of Physiology, The Cardiovascular System, Vol. 1. The Heart. Baltimore: Williams & Wilkins, pp 497-531, 1979
56.
56. Jugdutt BI. Left ventricular rupture threshold during the healing phase after myocardial infarction in the dog. Can J Physiol Pharmacol65:307-316, 1987
57.
57. Bergman I, Loxley R.Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem35:1961-1965, 1963
58.
58. Jugdutt BI, Joljart MJ, Khan MI. Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: Mechanistic insights into ventricular remodeling. Circulation94:94-101, 1996
59.
59. Jugdutt BI. Intravenous nitroglycerin unloading in acute myocardial infarction. Am J Cardiol68:52D-63D, 1991
60.
60. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE. Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. Circulation91:802-812, 1995
61.
61. Ogilvie RI. Comparative effects of vasodilator drugs on flow distribution and venous return. Can J Physiol Pharmacol63:1345-1355, 1985
62.
62. Hochman JS, Choo H.Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation75:299-306, 1987
63.
63. Boyle MP. Weisman HF. Limitation of infarct expansion and ventricular remodeling by late reperfusion. Study of time course and mechanism in a rat model. Circulation88:2872-2883, 1993
64.
64. Kim CB, Braunwald E.Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation88:2426-2436, 1993
65.
65. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P.Survival after an experimental myocardial infarction: Beneficial effects of long-term therapy with captopril. Circulation72: 406-412, 1985
66.
66. Jugdutt BI, Humen DP. Limitation of left ventricular hypertrophy by ACE inhibition after anterior Q-wave myocardial infarction. Cardiology89:283-290, 1998
67.
67. Yu C-M, Tipoe GL, Lai KW-H, Lau C-P.Effects of combination angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltrate and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol38:1207-1215, 2001
68.
68. Nayler WG. The effect of amlodipine on hypertensioninduced cardiac hypertrophy and reperfusion-induced calcium overload. J Cardiovasc Pharmacol12 (Suppl 7):S41-S44, 1988
69.
69. Vatner SF, Hintze TH. Effects of a calcium-channel antagonist on large and small coronary arteries in conscious dogs. Circulation66:579-588, 1982
70.
70. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina pectoris: An overview. Br Med J299:1187-1192, 1989
71.
71. Abemethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihdropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition. Clin Pharmacol Ther48:76-86, 1990
72.
72. Wang WZ, Matsumori A, Yamada T, et al. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation95:245-251, 1997
73.
73. Jugdutt BI. Delayed effects of early infarct-limiting therapies on healing. Circulation72:907-914, 1985
74.
74. Rinaldi CA, Linka AZ, Masani ND, et al. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. Circulation98:749-756, 1998
75.
75. Cohn JN, Ferrari R, Sharpe N, on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling—Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol35:569-582, 2000
